H. A. Fine

Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome

IDH1andIDH2Mutations in Gliomas

Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas

The future of high-grade glioma: Where we are and where are we going

Glioblastoma and Other Malignant Gliomas

Radiomics: Images Are More than Pictures, They Are Data

Medical management of brain tumors and the sequelae of treatment

Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

Malignant Gliomas in Adults

The causes and consequences of genetic heterogeneity in cancer evolution

Microtubule-binding agents: a dynamic field of cancer therapeutics

Glioblastoma multiforme: State of the art and future therapeutics

Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids

Management of glioblastoma: State of the art and future directions

2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis

Adoptive cell transfer as personalized immunotherapy for human cancer

Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab

Stathmin 1: a novel therapeutic target for anticancer activity

Artificial intelligence in cancer imaging: Clinical challenges and applications

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

Facile bio-synthesis of gold nanoparticles by using extract of Hibiscus sabdariffa and evaluation of its cytotoxicity against U87 glioblastoma cells under hyperglycemic condition

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

The 1p-Encoded Protein Stathmin and Resistance of Malignant Gliomas to Nitrosoureas

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)